Dublin, Jan. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021" report has been added to ResearchAndMarkets.com's offering.
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2021.
The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 provides the reader with the following key benefits:
In-depth understanding of royalty rate partnering deal trends since 2010
Analysis of the structure of royalty clauses with numerous real life case studies
Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed
Insight into the royalty terms included in a licensing agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Available deals and contracts are listed by:
Analyzing actual contract agreements allows assessment of the following:
What are the precise royalty rates granted?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
1.1. What are royalties?
1.2. History of royalty rates
1.3. Royalties in pharma and biotech
1.4. Royalties versus revenue share
1.5. Overview of the report
Chapter 2 - An overview of pharma and biotech royalty rates
2.1. Trends in royalty rates 2010-2021
2.2. Royalty rate disclosure in pharma and biotech
2.3. How do revenue shares figure?
2.4. A review of recent literature
2.5. Royalty rates in the future
Chapter 3 - Average royalty rates for pharma and biotech partnering
3.1. Royalty rates in early stage deals
3.2. Royalty rates by stage of development
3.3. Royalty rates by therapy area
Chapter 4 - The royalty clause in pharma and biotech deals
4.1. Partnering agreement structure
4.2. Structure of a typical royalty clause
4.3. Example royalty clauses
4.3.1. Case study 1: Merck Serono-Opexa Therapeutics
4.3.2. Case study 2: Aradigm - Grifols
4.3.3. Case study 3: Forect Laboratories - Trevena
4.3.4. Case study 4: Sage Therapeutics - University of California
Chapter 5 - Companies actively disclosing royalty rates
5.1. 25 most active companies in disclosing royalty rates
5.2. Top partnering deals by royalty rate
5.3. Top partnering deals by royalty rate
Chapter 6 - Royalty rate contract directory
Explore royalty rates within the deal contract document to gain greater insight
Appendix 1 - Royalty rates in deals - by company A-Z
Appendix 2 - Royalty rates in deals - by therapy area
Appendix 3 - Royalty rates in deals - by stage of development at signing
Appendix 4 - Royalty rates in deals - by technology type
Appendix 5 - Royalty rate references
Appendix 6 - Resources
Appendix 7 - Deal type definitions
Appendix 8 - Example royalty rate deal contract document
For more information about this report visit https://www.researchandmarkets.com/r/fuxb7
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900